Rouven Bergmann, Chief Financial Officer of Medidata Solutions, Inc. (MDSO) Just Unloaded Shares; MANZ AUTOMATION (MANZF) Shorts Decreased By 10.05%

An insider Rouven Bergmann who is Chief Financial Officer of Medidata Solutions Inc sold some 3,000 shares of the New York-based company worth $210,000 US Dollars based on $70.0 for each share. In the last 30 days, he also sold 2,000 shares with a total value $132,920 USD. The probability of this sell remaining ignored is little, with the Chief Financial Officer right now possessing 84,775 shares — that is 0.14% of the total market capitalization of the Company. Rouven finished this trade on January 26, 2018. The filing is available for free here at the Security and Exchange Commission website.

MANZ AUTOMATION (OTCMKTS:MANZF) had a decrease of 10.05% in short interest. MANZF’s SI was 18,800 shares in January as released by FINRA. Its down 10.05% from 20,900 shares previously. It closed at $43 lastly. It is down 0.00% since January 27, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock increased 2.69% or $1.88 during the last trading session, reaching $71.74. About 427,882 shares traded. Medidata Solutions, Inc. (NASDAQ:MDSO) has risen 68.37% since January 27, 2017 and is uptrending. It has outperformed by 51.67% the S&P500.

Among 17 analysts covering Medidata Solutions Inc. (NASDAQ:MDSO), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Medidata Solutions Inc. has $92.0 highest and $35 lowest target. $75.86’s average target is 5.74% above currents $71.74 stock price. Medidata Solutions Inc. had 39 analyst reports since July 22, 2015 according to SRatingsIntel. On Monday, August 21 the stock rating was maintained by Jefferies with “Hold”. SunTrust upgraded Medidata Solutions, Inc. (NASDAQ:MDSO) on Friday, February 10 to “Buy” rating. On Sunday, September 17 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. On Tuesday, April 26 the stock rating was initiated by Leerink Swann with “Market Perform”. Topeka Capital Markets maintained it with “Hold” rating and $53 target in Friday, September 25 report. The stock of Medidata Solutions, Inc. (NASDAQ:MDSO) earned “Market Perform” rating by Wells Fargo on Thursday, July 21. Deutsche Bank initiated Medidata Solutions, Inc. (NASDAQ:MDSO) on Friday, December 8 with “Buy” rating. The firm earned “Buy” rating on Friday, February 10 by Suntrust Robinson. Wells Fargo upgraded the stock to “Buy” rating in Friday, December 1 report. Topeka Capital Markets upgraded it to “Buy” rating and $50 target in Wednesday, October 28 report.

Investors sentiment increased to 1.23 in 2017 Q3. Its up 0.06, from 1.17 in 2017Q2. It increased, as 38 investors sold Medidata Solutions, Inc. shares while 60 reduced holdings. 33 funds opened positions while 88 raised stakes. 59.30 million shares or 4.96% more from 56.50 million shares in 2017Q2 were reported. Vanguard Grp Inc has 0.02% invested in Medidata Solutions, Inc. (NASDAQ:MDSO) for 4.69 million shares. American Capital Management stated it has 1.74% of its portfolio in Medidata Solutions, Inc. (NASDAQ:MDSO). Us Bancorp De owns 8,624 shares or 0% of their US portfolio. 219 were reported by Whittier Trust Com Of Nevada. 143,797 are held by Strs Ohio. Sg Americas Limited Liability Corporation accumulated 1,896 shares. Assetmark Incorporated has 678 shares. Polar Limited Liability Partnership accumulated 262,226 shares. Arcadia Invest Management Mi holds 47,005 shares or 1.12% of its portfolio. Tiedemann Wealth Ltd Limited Liability Company owns 12,174 shares for 0.01% of their portfolio. Barclays Public Ltd holds 0% or 11,095 shares in its portfolio. Benjamin F Edwards & invested 0% in Medidata Solutions, Inc. (NASDAQ:MDSO). Spectrum Mngmt Group Inc holds 0% or 12 shares. The Ontario – Canada-based Canada Pension Plan Invest Board has invested 0.18% in Medidata Solutions, Inc. (NASDAQ:MDSO). Art Advsr Limited Com holds 2,600 shares or 0.01% of its portfolio.

Medidata Solutions, Inc. provides cloud solutions for life sciences worldwide. The company has market cap of $4.20 billion. It offers Medidata Clinical Cloud that provides a software-as-a-service platform of technology and data analytics solutions to optimize activities across clinical development. It has a 102.63 P/E ratio. The companyÂ’s platform solutions includes Plan Study that addresses the areas to ensure optimal study design, grant development and negotiation, and investigator payments; and Support Sites, which provides robust risk management, reduced source document verification, real-time monitoring, on-time, accurate payments.

Analysts await Medidata Solutions, Inc. (NASDAQ:MDSO) to report earnings on February, 8. They expect $0.18 EPS, down 21.74% or $0.05 from last year’s $0.23 per share. MDSO’s profit will be $10.53M for 99.64 P/E if the $0.18 EPS becomes a reality. After $0.22 actual EPS reported by Medidata Solutions, Inc. for the previous quarter, Wall Street now forecasts -18.18% negative EPS growth.

Since August 15, 2017, it had 0 insider buys, and 3 selling transactions for $637,470 activity. Bergmann Rouven sold $131,900 worth of Medidata Solutions, Inc. (NASDAQ:MDSO) on Tuesday, December 19. 5,000 Medidata Solutions, Inc. (NASDAQ:MDSO) shares with value of $372,650 were sold by Capone Michael L.